Keyword: Kenneth Frazier

Merck CEO Kenneth Frazier worries new JAMA studies on pharma profitability ill exacerbate the ongoing political debate about drug pricing.

Merck's planned spinoff will allow the company to focus on oncology and other fast-growing sectors, CEO Ken Frazier said. Analysts aren't convinced.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.

Merck CEO Ken Frazier knows the industry is in the political "crosshairs," but he cautioned against policies that could "hurt innovation."

Big Pharma CEOs have their own way of cozying up to the world’s second largest pharmaceutical market—by getting themselves Chinese names.

Merck CEO Ken Frazier and his colleagues vowed during the company's Investor Day that a healthy pipeline will drive margin expansion.

Merck is scouting replacements for CEO Ken Frazier with a preference toward an internal candidate, Bloomberg reports.

With resolutions on the ballot at six top U.S. drugmakers, investors aim to learn how drug pricing affects executive pay.

Ken Frazier’s total compensation for 2018 was $20.9 million, up from $17.6 million in 2017, enough to put him among the industry's highest paid.